Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

261. Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events

Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events Mirabegron (Betmiga▼): risk of severe hypertension and associated cerebrovascular and cardiac events - GOV.UK GOV.UK uses cookies to make the site simpler. Search Mirabegron (Betmiga▼): risk of severe hypertension and associated cerebrovascular and cardiac events From: Published: 14 October 2015 Therapeutic area: and Mirabegron is now contraindicated in patients with severe uncontrolled (...) hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension. Contents Key updated safety advice for healthcare professionals: Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both) Blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension Please report suspected side

MHRA Drug Safety Update2015

262. The double challenge of resistant hypertension and chronic kidney disease.

The double challenge of resistant hypertension and chronic kidney disease. Resistant hypertension is defined as blood pressure above goal despite adherence to a combination of at least three optimally dosed antihypertensive medications, one of which is a diuretic. Chronic kidney disease is the most frequent of several patient factors or comorbidities associated with resistant hypertension. The prevalence of resistant hypertension is increased in patients with chronic kidney disease, while (...) chronic kidney disease is associated with an impaired prognosis in patients with resistant hypertension. Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic, should be complemented by the sequential addition of other antihypertensive drugs. New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronic kidney disease. We discuss resistant

Lancet2015

263. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury.

Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. BACKGROUND: In patients with traumatic brain injury, hypothermia can reduce intracranial hypertension. The benefit of hypothermia on functional outcome is unclear. METHODS: We randomly assigned adults with an intracranial pressure of more than 20 mm Hg despite stage 1 treatments (including mechanical ventilation and sedation management) to standard care (control group) or hypothermia (32 to 35°C) plus standard care

NEJM2015

265. Beta-blockers in Uncomplicated Hypertension: Is it Time for Retirement?

Beta-blockers in Uncomplicated Hypertension: Is it Time for Retirement? Beta-blockers in Uncomplicated Hypertension: Is it Time for Retirement? | Clinical Correlations Beta-blockers in Uncomplicated Hypertension: Is it Time for Retirement? October 7, 2015 By Robin Guo, MD Peer Reviewed Beta-blockers were one of the first modern medications used for the treatment of blood pressure. Before 1950, treatment options for hypertension were limited. The alphabet soup of medications—reserpine (...) of action was via inhibition of beta-adrenergic receptors, reduction of cardiac output, and decrease in sympathetic outflow ( ). Despite beta-blockers’ odd mechanism of action, they were (and still are) as effective as the earlier anti-hypertensive agents in decreasing blood pressure ( , ). Beta-blockers became extremely popular once they were found to have many fewer side effects than the older generation of drugs,. Since then, many derivatives and generations of the beta-blocker have come into use

Clinical Correlations2015

266. Travoprost (Travatan) - decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma

Travoprost (Travatan) - decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma Published 12 October 2015 Product Update: Travoprost 40 micrograms/mL eye drops (Travatan®) SMC No. (1091/15) Alcon Eye Care UK Ltd 4 September 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission travoprost (Travatan ® ) is accepted for use within NHS Scotland. Indication under review: decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma. In a randomised, double-masked study of paediatric patients with glaucoma or ocular hypertension, travoprost was demonstrated to be non-inferior to a beta blocker eye drop preparation in terms

Scottish Medicines Consortium2015

267. Calcium channel blockers for pulmonary arterial hypertension.

Calcium channel blockers for pulmonary arterial hypertension. BACKGROUND: Pulmonary arterial hypertension (PAH) is one of several forms of pulmonary hypertension: a chronic disease of the pulmonary vasculature. The mean age at diagnosis is around 50 years old, with increasing prevalence in people over 70 years old (10% to 17%). The median survival to be approximately seven years with one-, three-, five-, and seven-year survival rates from time of diagnostic right-sided heart catheterization

Cochrane2015

268. Is Shock Index a Valid Predictor of Mortality in Emergency Department Patients With Hypertension, Diabetes, High Age, or Receipt of beta- or Calcium Channel Blockers?

Is Shock Index a Valid Predictor of Mortality in Emergency Department Patients With Hypertension, Diabetes, High Age, or Receipt of beta- or Calcium Channel Blockers? 26144893 2015 12 28 2016 05 02 2015 12 28 1097-6760 67 1 2016 Jan Annals of emergency medicine Ann Emerg Med Is Shock Index a Valid Predictor of Mortality in Emergency Department Patients With Hypertension, Diabetes, High Age, or Receipt of β- or Calcium Channel Blockers? 106-113.e6 10.1016/j.annemergmed.2015.05.020 S0196-0644(15 (...) )00425-4 Shock index is a widely reported tool to identify patients at risk for circulatory collapse. We hypothesize that old age, diabetes, hypertension, and β- or calcium channel blockers weaken the association between shock index and mortality. This was a cohort study of all first-time emergency department (ED) visits between 1995 and 2011 (n=111,019). We examined whether age 65 years or older, diabetes, hypertension, and use of β- or calcium channel blockers modified the association between shock

EvidenceUpdates2015

269. Tafluprost + timolol (Taptiqom) - Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension

Tafluprost + timolol (Taptiqom) - Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension Published 07 September 2015 Product Update: tafluprost 15micrograms/mL and timolol 5mg/mL preservative-free eye drops (Taptiqom ® ) SMC No. (1085/15) Santen GmbH 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission tafluprost 15 micrograms/mL and timolol 5mg/mL preservative-free eye drops (Taptiqom ® ) are accepted for restricted use within NHS Scotland. Indication under review: Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit

Scottish Medicines Consortium2015

270. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received (...) hypertension, disease progression, or unsatisfactory long-term clinical response. RESULTS: The primary analysis included 500 participants; 253 were assigned to the combination-therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group. A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, respectively, and in 31% of the pooled-monotherapy group (the two monotherapy groups combined). The hazard ratio for the primary end point

NEJM2015

271. Fast-track protocols in devascularization for cirrhotic portal hypertension.

Fast-track protocols in devascularization for cirrhotic portal hypertension. 26248248 2015 08 07 2015 12 17 2016 08 15 1806-9282 61 3 2015 May-Jun Revista da Associacao Medica Brasileira (1992) Rev Assoc Med Bras (1992) Fast-track protocols in devascularization for cirrhotic portal hypertension. 250-7 10.1590/1806-9282.61.03.250 S0104-42302015000300250 fast-tract surgery (FTS) has been rapidly embraced by surgeons as a mechanism for improving patient care and driving down complications (...) -4230 IM Adult Clinical Protocols Female Follow-Up Studies Humans Hypertension, Portal surgery Length of Stay Liver Cirrhosis complications Male Middle Aged Perioperative Care methods Postoperative Care Postoperative Nausea and Vomiting Prospective Studies Splenectomy Surgical Wound Infection Time Factors Treatment Outcome Urinary Tract Infections Vagus Nerve surgery 2014 07 27 2014 10 22 2015 8 7 6 0 2015 8 8 6 0 2015 12 19 6 0 ppublish 26248248 S0104-42302015000300250 10.1590/1806-9282.61.03.250

Revista da Associacao Medica Brasileira (1992)2015

273. Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION)

Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION) 26063762 2015 07 14 2015 09 24 2016 02 18 1524-4539 132 2 2015 Jul 14 Circulation Circulation Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION). 93-100 10.1161/CIRCULATIONAHA.115.015464 Hypertension control rates (...) remain suboptimal. Pharmacists' scope of practice is evolving, and their position in the community may be ideal for improving hypertension care. We aimed to study the impact of pharmacist prescribing on blood pressure (BP) control in community-dwelling patients. We designed a patient-level, randomized, controlled trial, enrolling adults with above-target BP (as defined by Canadian guidelines) through community pharmacies, hospitals, or primary care teams in 23 communities in Alberta. Intervention

EvidenceUpdates2015

274. Baroreflex Activation Therapy for Treatment-Resistant Hypertension: the Barostim neo

Baroreflex Activation Therapy for Treatment-Resistant Hypertension: the Barostim neo Baroreflex Activation Therapy for Treatment-Resistant Hypertension: the Barostim neo | CADTH.ca Find the information you need Baroreflex Activation Therapy for Treatment-Resistant Hypertension: the Barostim neo Baroreflex Activation Therapy for Treatment-Resistant Hypertension: the Barostim neo Published on: July 15, 2015 Project Number: EH0027 Product Line: Issue: 136 Result type: Report This bulletin (...) was originally published in May 2015. In July 2015, minor changes in wording were made on page 2 (paragraphs 3, 4, and 7), and on page 6 (paragraph 3) at the request of the manufacturer, CVRx. Summary Of the 20% of Canadian adults diagnosed with hypertension, a small number have treatment-resistant hypertension — that is, their blood pressure remains above the target level despite the use of an optimal combination of at least three antihypertensive drugs, including a diuretic. Baroreflex activation therapy

CADTH - Issues in Emerging Health Technologies2015

276. Calcium supplementation for prevention of primary hypertension.

Calcium supplementation for prevention of primary hypertension. BACKGROUND: Hypertension is a major public health problem that increases the risk of cardiovascular and kidney diseases. Several studies have shown an inverse association between calcium intake and blood pressure. As small reductions in blood pressure have been shown to produce rapid reductions in vascular disease risk even in individuals with normal blood pressure ranges, this review intends to evaluate the effect of calcium (...) supplementation in normotensive individuals as a preventive health measure. OBJECTIVES: To assess the efficacy and safety of calcium supplementation versus placebo or control for reducing blood pressure in normotensive people. SEARCH METHODS: We searched the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomised controlled trials up to October 2014. The WHO International Clinical

Cochrane2015

277. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.

Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. IMPORTANCE: The association between selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and risk of persistent pulmonary hypertension of the newborn (PPHN) has been controversial since the US Food and Drug Administration issued a public health advisory in 2006. OBJECTIVE: To examine the risk of PPHN associated with exposure to different antidepressant medication

JAMA2015

279. Hypertension - Diagnosis and Management

Hypertension - Diagnosis and Management Hypertension - Diagnosis and Management - Province of British Columbia Search default_collection default_frontend MENU theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Health theme_2_collection theme_2_frontend theme_2_collection theme_2_frontend Birth, Adoption, Death, Marriage & Divorce theme_4_collection theme_4_frontend (...) theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration theme_15_collection theme_15_frontend theme_15_collection theme_15_frontend Family & Social Supports default_collection default_frontend default_collection default_frontend Data Section Navigation Hypertension - Diagnosis and Management Effective Date: March 1, 2015 Revised Date: June 22, 2016 Recommendations and Topics Scope This guideline provides recommendations on how to diagnose and manage hypertension (HTN) in adults aged ≥ 19

Clinical Practice Guidelines and Protocols in British Columbia2015

280. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.

Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. IMPORTANCE: Uncertainty remains about the efficacy of folic acid therapy for the primary prevention of stroke because of limited and inconsistent data. OBJECTIVE: To test the primary hypothesis that therapy with enalapril and folic acid is more effective in reducing first stroke than enalapril alone among Chinese adults with hypertension. DESIGN, SETTING (...) , AND PARTICIPANTS: The China Stroke Primary Prevention Trial, a randomized, double-blind clinical trial conducted from May 19, 2008, to August 24, 2013, in 32 communities in Jiangsu and Anhui provinces in China. A total of 20,702 adults with hypertension without history of stroke or myocardial infarction (MI) participated in the study. INTERVENTIONS: Eligible participants, stratified by MTHFR C677T genotypes (CC, CT, and TT), were randomly assigned to receive double-blind daily treatment with a single-pill

JAMA2015